Schrödinger, Inc. (SDGR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Schrödinger said its 1Q performance slightly exceeded guidance and that growth was broad-based, driven by existing customers increasing usage and new products being added. The company reiterated its full-year outlook, suggesting no material change to the forward setup. The update is modestly positive, but the article is mainly a conference discussion rather than new financial disclosure.

Analysis

The key signal is not the modest beat itself but the breadth of consumption: when usage rises across existing customers and product adoption expands, it usually means the platform is moving from evaluation to embedment. That matters because software-like recurring revenue in drug discovery tends to inflect with a lag; once teams build workflows around a tool, churn becomes operationally expensive and upsell probability increases over the next 2-4 quarters. The market is likely still underappreciating how much of SDGR’s value is driven by account depth rather than net-new logos.

The second-order read-through is competitive. If large customers are scaling usage, smaller point-solution vendors and legacy modeling tools become more vulnerable, because procurement committees will standardize around a platform that can absorb more workflows under one contract. That creates a flywheel: more usage improves the product/data moat, which raises switching costs and reduces pricing pressure, especially in large pharma where integration risk is a bigger hurdle than sticker price.

The main risk is timing. Even if demand is improving, software revenue in life sciences can be lumpy, and biotech budgets can still re-tighten if capital markets weaken or pharma prioritizes cost controls. The next catalyst window is the next 1-2 quarterly updates: if management continues to show multi-product expansion and customer concentration is not worsening, the multiple can re-rate before the underlying therapeutics pipeline contributes materially. If, however, usage gains are driven by a few large accounts rather than broad adoption, the growth narrative becomes much more fragile.

Key Decisions for Investors

• Go long SDGR on pullbacks over the next 1-3 weeks; risk/reward favors a tactical entry if the stock is still discounting execution risk despite improving customer expansion signals.
• Pair trade: long SDGR / short a weaker life-science software or tools name with more exposed budget cyclicality; thesis is that platform share gain should outpace the basket if pharma workflow consolidation continues over 2-4 quarters.
• Buy near-dated call spreads in SDGR into the next earnings window; the cleanest upside catalyst is another quarter of broad-based usage growth, while downside is limited by already-anchored expectations from the guide reiteration.
• If SDGR rallies sharply on the conference tape, trim into strength rather than chase; the setup is better for accumulating on any post-event consolidation unless the company later quantifies sustained net retention expansion.